



Advances in Small-Molecule C-KIT/PDGFR α Inhibitors for the Treatment of Gastrointestinal Stromal Tumors

Xuan Zheng^{1#} Hong Liang^{1#} Yang Zhou¹ Xiaoyun Lu^{1*}

¹ State Key Laboratory of Bioactive Molecules and Druggability Assessment, International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education, School of Pharmacy, Jinan University, Guangzhou, People's Republic of China

Pharmaceut Fronts 2024;6:e323–e335.

Address for correspondence: Xiaoyun Lu, PhD, State Key Laboratory of Bioactive Molecules and Druggability Assessment, International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education, School of Pharmacy, Jinan University, 855 Xingye Avenue, Guangzhou 510632, People's Republic of China (e-mail: luxy2016@jnu.edu.cn).

Abstract

Keywords

- PDGFR α
- C-KIT
- GISTs
- kinase inhibitors
- clinical resistance

Stem cell factor receptor (*C-KIT*) or platelet-derived growth factor receptor α (*PDGFR α*) gene mutations have been identified as oncogenic drivers for most gastrointestinal stromal tumors (GISTs). Thus, small-molecule inhibitors of C-KIT or PDGFR α have emerged as effective treatments for GISTs. Although the currently approved first- to fourth-line drugs are initially effective against GISTs, the inevitable development of drug resistance remains an unmet challenge. To address secondary mutations leading to drug resistance, several novel selective C-KIT/PDGFR α small-molecule inhibitors have been developed and clinically studied. This review summarizes the pathogenesis, treatment, and drug resistance mechanisms of GISTs and briefly describes current challenges and future efforts for GIST treatment using small-molecule kinase inhibitors.

Introduction

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors in the gastrointestinal tract, accounting for 1 to 3% of gastrointestinal malignancies.¹ Most GISTs occur in the stomach (50–70%) and small intestine (20–30%), whereas these tumors are relatively uncommon in the rectum (10–20%) and esophagus (0–6%). Meanwhile, GISTs in the mesentery omentum and retroperitoneum are rare.² Mutations in the stem cell factor receptor (*C-KIT*) and platelet-derived growth factor receptor α (*PDGFR α*) genes have proven to be the main pathogenic drivers of GISTs, accounting for 85 to 95% of all cases.^{3,4} *C-KIT* gene mutations are present in 60 to 85% of GIST tumors, whereas 5 to 10% of GISTs carry *PDGFR α* gene mutations. GISTs without *C-KIT* or *PDGFR α* gene mutations are defined as

wild-type GISTs, and their pathogenesis has not been fully clarified. The possible pathogenic factors include the deletion of succinate dehydrogenase B, activation of insulin growth factor 1 receptor, mutation of the oncogene *BRAF*, and neurofibromatosis type I.⁵ This article mainly focuses on GISTs driven by *C-KIT* and *PDGFR α* mutations, which have been effectively treated by small-molecule kinase inhibitors.

C-KIT and PDGFR α

C-KIT and PDGFR α , encoded by the *C-KIT* and *PDGFR α* genes, respectively, belong to the class III receptor tyrosine kinase (RTK) family. Both proteins consist of an extracellular region, a transmembrane region, and an intracellular region.⁶ As shown in ►Fig. 1, the extracellular region encoded by *C-KIT* exon 9 or *PDGFR α* exons 3–10 consists of five immunoglobulin-like domains, which identify and bind to the corresponding ligand to cause receptor dimerization and tyrosine

These authors contributed equally to this work.

received
October 28, 2023
accepted
September 6, 2024
article published online
October 17, 2024

DOI <https://doi.org/10.1055/s-0044-1791541>.
ISSN 2628-5088.

© 2024. The Author(s).
This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (<https://creativecommons.org/licenses/by/4.0/>)
Georg Thieme Verlag KG, Rüdigerstraße 14, 70469 Stuttgart, Germany




Fig. 1 C-KIT and PDGFR α signaling pathway.

kinase autophosphorylation. The intracellular region contains a juxtamembrane domain (JMD) region encoded by C-KIT exon 11 or PDGFR α exon 12 and a kinase domain. The kinase domain includes an adenosine triphosphate (ATP)-binding domain encoded by C-KIT exons 13–14 or PDGFR α exon 14 and an activation loop (AL) switch encoded by C-KIT exons 17–18 or PDGFR α exons 18–19.

C-KIT and PDGFR α both exist as inactive monomers in the absence of ligand binding. Once bound to ligands, the two monomer receptors form dimers on the membrane and activate protease activity and downstream signal transduction pathways, such as the SRC/RAC1, RAS/RAF, and PI3K/AKT pathways, thereby regulating cell growth and proliferation.^{7,8} Mutations allow C-KIT and PDGFR α to maintain dimerization and self-phosphorylation without ligand binding, perpetuating receptor-activated signaling and resulting in the activation of downstream effectors that ultimately mediate abnormal cell survival, proliferation, and differentiation (**Fig. 1**).^{6,9,10}

The configuration of these kinases is mainly controlled by JMD and AL moieties. In PDGFR α , JMD consists of residues 555–586, and it is associated with kinase folding. AL in PDGFR α is a long flexible peptide segment (**Fig. 2**). JMD and AL regulate cellular kinase activity by controlling the kinase conformation through a double-switching mechanism.¹¹ When C-KIT or PDGFR α is in an autoinhibited inactivated state, JMD is embedded, and it has multiple contacts with the catalytic site between the N-lobe and C-lobe. Numerous conserved residues within this domain are indispensable for binding with hydrophobic interactions, preventing conformational changes in the active kinase state and substrate binding. Deletion or point mutation of key residues within JMD disrupts these mutual contacts and releases JMD from the kinase fold, resulting in nonautoinhibition activation. The conformation of AL, another key regulatory domain, controls the access to catalytic sites and kinase activity. AL of C-KIT/PDGFR α spans 27 residues




Fig. 2 General structure of PDGFR α (PDB: 5K5X). AL, activation loop; JMD, juxtamembrane domain.

from the conserved aspartate–phenylalanine–glycine (DFG) sequence to the alanine–proline–glutamate sequence. C-KIT D816 and PDGFR α D842 have multipolar interactions within the adjacent helix of AL, supporting the DFG-out conformation of AL. Therefore, missense mutations or insertions/deletions will maintain AL in a DFG-out conformation, resulting in constitutive kinase activity. For C-KIT/PDGFR α , a shift in AL from the DFG-out conformation to the DFG-in conformation is the primary mechanism of kinase activation (**Fig. 3**).

Oncogenic kinase mutations disrupt one or multiple regulatory switching mechanisms, causing switch dysfunction and the loss of physiological conformational control. Mutations in GISTs mainly affect the exons encoding the functional domains of C-KIT/PDGFR α . Primary C-KIT mutations occur mostly in exons 9 and 11 and more rarely in exons 13 and 17 (**Table 1**). Among them, primary C-KIT mutations in exon 11 are the most common (accounting for 60–70% of GISTs), and they are mainly induced by interstitial deletions of codons 550–579. Conversely, point mutations are limited to four codons (557, 559, 560, and 576).¹ Although the incidence is low, mutations of this switch will disrupt the inactive conformation of C-KIT, causing a conformational balance shift to the active form. The primary C-KIT mutation in exon 9 is the second most frequent mutation, being present in 10% of GISTs. Most of these lesions arise in the small intestine, and the mutations primarily involve repeats of residues 502–503.² The conformational changes caused by this mutation can simulate ligand binding, leading to dimerization and sustained activation. Contrarily, secondary mutations most commonly occur in exon 13 or 17 of C-KIT, and these mutations, primarily comprising point mutations, insertions, and repeat mutations, are relatively rare. PDGFR α is the second most commonly mutated oncogene in GISTs. PDGFR α exon 18 mutations are most common (6% of GISTs), whereas mutations in exons 12 and 14 are rare (<2% of GISTs).¹² Among them, single-base substitutions in exon 18, especially D842V, represent the most common PDGFR α mutation in GISTs (**Table 1**).




Fig. 3 Kinase domain conformation states for C-KIT and PDGFR α . AL, activation loop; JMD, juxtamembrane domain.

In general, a small number of primary mutations and almost all secondary mutations in C-KIT/PDGFR α are located either in the main AL switch or ATP switch pocket.¹³ Secondary mutations that alter the tyrosine kinase domain of C-KIT or PDGFR α represent the primary mechanism of secondary resistance to targeted drugs in patients with GIST. However, some patients exhibit acquired drug resistance without secondary mutations, which might be associated with gene deletion, receptor amplification, signaling bypass, or the activation of other RTKs.

Small-Molecule Kinase Inhibitors

Surgical excision is the major treatment for early-stage GISTs. However, nearly 50% of patients with GISTs experience postoperative recurrence or metastasis after complete tumor resection.¹⁴ The efficacy of C-KIT/PDGFR α inhibitors has been gradually affirmed for metastatic or unresectable GISTs. In this section, we provide a brief introduction to clinically applied therapeutic drugs for GISTs, including marketed drugs such as imatinib, sunitinib, regorafenib, ripretinib, and avapritinib, as well as crenolanib, bezuclastinib, NB003, THE-630, and IDRX-42, which are currently in clinical development.

Marketed Small-Molecule Kinase Inhibitors

The type II kinase inhibitors imatinib, sunitinib, and regorafenib, which are the approved first-, second-, and third-line treatments for GISTs, respectively, are effective targeted therapies for advanced GISTs. However, they only partially inhibit mutated C-KIT or PDGFR α , and they have limited activity against AL mutations. Ripretinib and avapritinib, two next-generation approved tyrosine kinase inhibitors (TKIs), exert stronger therapeutic effects against GISTs. The structure, type, date of approval, indication, and effects against various mutations in C-KIT and PDGFR α are summarized for the five aforementioned marketed drugs in **Table 2**.

Imatinib, Sunitinib, and Regorafenib






Imatinib is a multitargeted small-molecule TKI of C-KIT, PDGFR α , and ABL. This drug was approved for the first-line treatment of inoperable and metastatic GISTs in 2002. Imatinib is a type II kinase inhibitor that binds to the inactive conformation of C-KIT/PDGFR α . After treatment with imatinib, 80% of patients with advanced GISTs exhibit a response after 2 to 3 months. Median overall survival (OS) is approximately 57 to 60 months, and approximately 50% of patients

Table 1 Mutation types of C-KIT and PDGFR α and their frequency

Gene	Exon	Type of mutation	Domain affected	Frequency
C-KIT	9	Insertion	Ligand-binding	≈10%
	11	Deletion	JMD	60–70%
		Insertion		
		Single-base substitution		
	13	Single-base substitution	ATP-binding pocket	≈1%
	17	Single-base substitution	AL	≈1%
PDGFR α	12	Deletion	JMD	≈1%
		Insertion		
		Single-base substitution		
	14	Single-base substitution	ATP-binding pocket	<1%
	18	Single-base substitution	AL	≈6%
Wild type	/	/	/	10–15%

Abbreviations: AL, activation loop; ATP, adenosine triphosphate; JMD, juxtamembrane domain.

Table 2 Approved drugs for GISTs

Name	Imatinib	Sunitinib	Regorafenib	Ripretinib	Avapritinib
Structure					
Type	II	II	II	II	I
Approved time	2002	2006	2013	2021	2020
Indication for advanced GISTs	First-line	Second-line	Third-line	Fourth-line	PDGFRα exon 18
G-KIT mutation	Exon 9	☑	☑	☑	Q
	Exon 11	☑	☑	☑	☑
	Exon 13 (V654A)	Q	Q	☑	Q
	Exon 14 (T670I)	Q	☑	☑	Q
	Exon 17 (D816V/H)	Q	Q	☑	☑
	Exon 17 (D816E)	Q	☑	☑	☑
	Exon 18 (D842V)	Q	Q	Q	☑
PDGFRα mutation					

Abbreviation: GISTs, gastrointestinal stromal tumors.
Note: ☑ sensitive; Q resistant.

survive longer than 5 years.¹⁵ However, the majority of patients eventually experience disease progression. In total, 10 to 20% of patients with GISTs display primary resistance to imatinib, such as patients carrying the D842V mutation in PDGFR α exon 18 and patients with wild-type GISTs, and 50% of patients develop secondary resistance to imatinib. Most secondary C-KIT mutations after imatinib treatment occur in exons 13 (V654A), 14 (T670I), and 17 (e.g., D816H/V). Conversely, secondary PDGFR α mutations, especially D842V, mainly arise in exon 18 (►Table 2).^{16,17} Resistance is caused by multiple secondary mutations within the ATP-binding domain and AL. The co-crystal of imatinib complexed with C-KIT suggests that imatinib makes contact with V654 in the side chain and forms a hydrogen bond with the gatekeeper (GK) residue T670. The mutations in the ATP-binding pocket, including V654A in exon 13 and T670I in exon 14, are predicted to decrease the binding affinity of imatinib for the kinase (►Fig. 4).^{18,19} Meanwhile, AL mutations result in the conversion of C-KIT/PDGFR α from the DFG-out conformation to the DFG-in conformation, thereby interfering with the binding of imatinib and reducing its inhibitory activity.

Sunitinib, a multitargeted TKI with activity against PDGFR α/β , C-KIT, VEGFR1/2/3, and RET, was approved as a second-line treatment for patients with advanced GISTs after the development of resistance or intolerance to imatinib.²⁰ In addition to patients with wild-type C-KIT, those with exon 9 mutations, as well as those carrying secondary mutations in exon 13 or 14, including V654A and T670I, have better responses to sunitinib because the binding of sunitinib to C-KIT is not hindered by these mutations (►Table 2).^{21,22} However, sunitinib binds to the DFG-out state of C-KIT/PDG-

FR α similarly to imatinib, resulting in poor inhibitory effects when these kinases carry AL mutations.²³

Regorafenib, a multitargeted kinase inhibitor targeting VEGFR, PDGFR α/β , C-KIT, RET, and RAF1, was approved as a third-line treatment for advanced GISTs after imatinib and sunitinib failure or intolerance by the Food and Drug Administration (FDA) in 2013.²⁴ Regorafenib also binds to the inactive conformation of C-KIT/PDGFR α . Concerning secondary C-KIT mutations, regorafenib exhibits a complementary activity profile to sunitinib. Regorafenib displays potent activity against several exon 17 mutations in C-KIT, but it is ineffective against the D816V/H mutation. The drug has poor efficacy against the common secondary imatinib resistance mutation V654A in C-KIT exon 13, but it is effective against the T670I mutation in exon 14. Furthermore, regorafenib also has a poor inhibitory effect against D842V-mutated PDGFR α (►Table 2). Additionally, the more severe side effects of sunitinib and regorafenib, such as diarrhea and fatigue, limit their clinic application.²⁵

Whereas the aforementioned multitargeted TKIs can be used to treat advanced GISTs, clinical resistance attributable to AL mutations in C-KIT or PDGFR α remains a challenge. Imatinib, sunitinib, and regorafenib are type II inhibitors that only bind to the inactive forms of C-KIT and PDGFR α . Secondary mutations in AL cause a shift to the active conformation, reducing the ability of inhibitors to bind to the target. Ripretinib and avapritinib, as recently approved next-generation TKIs, are particularly designed to address these issues.

Ripretinib

C-KIT and PDGFR α are structurally similar dual-switch kinases consisting of an inhibitory switch and an AL switch, and their kinase activity is regulated by the kinase switch pocket. Ripretinib is a type II C-KIT/PDGFR α kinase inhibitor with a unique dual mechanism of action that permits it to act on both switches.²⁶ Ripretinib exhibits ideal inhibitory activity against the full spectrum of primary and secondary resistance mutations in C-KIT and PDGFR α , including AL mutations, which were previously believed to only be achieved by type I inhibitors. In a pivotal phase III clinical trial, ripretinib produced good outcomes in patients with GISTs, including progression-free survival (PFS) of 6.3 months and OS of 15.1 months.²⁷ Based on these promising clinical results, ripretinib was approved by the FDA in May 2020 for the fourth-line treatment of advanced GISTs in adults who previously received three or more kinase inhibitors.

Notably, ripretinib is a “switch-controlled” kinase inhibitor that binds to the ATP-binding pocket, blocking the kinase from adopting an active state and stabilizing the kinase in an inactive state. The co-crystal structure of DP-2976, a closely related analog of ripretinib, with C-KIT demonstrated the switch control design concept of the drug. Ripretinib binds to the DFG-out active conformation with the urea moiety, forming a hydrogen bond with switched E640, which plays an antagonist's role in maintaining the AL switch in an inactive type II state. The terminal phenyl ring of ripretinib takes over the interior




Fig. 4 The X-ray crystal structure of imatinib complexed with C-KIT (PDB ID: 1T46). C-KIT is shown by a white cartoon. Key residues and hydrogen bonds are represented by sticks and black dashed lines, respectively.




Fig. 5 The X-ray crystal structure of DP-2976 complexed with C-KIT (PDB ID: 6MOB). The red box presents the interior R-spine within the switch pocket formed by V643, L647, I653, V654, L783, H790, and I808.

R-spine within the switch pocket formed by surrounding residues, thereby stabilizing the AL switch phenyl side chain of F811 (DFG motif) in a type II inactive state. Furthermore, the fused pyridone ring of ripretinib forms extensive hydrophobic and van der Waals interactions with switched C809 and F811, further keeping the AL switch in a type II inactive state (**Fig. 5**).²⁶

Despite the ideal inhibitory activity of ripretinib against most C-KIT/PDGFR α mutations and the improvement in survival in patients with GISTs, disease progression occurs in some patients. The resistance mechanisms associated with disease progression have not been well defined, but it is possibly associated with resistance mutations in the ATP-binding pocket, as well as C-KIT/PDGFR α -independent mechanisms involving the PI3K and RAS/RAF pathways.²⁸ Therefore, it is necessary to develop the next generation of C-KIT/PDGFR α inhibitors with better therapeutic efficacy.

Avapritinib

Avapritinib is a potent and selective type I/II C-KIT/PDGFR α inhibitor targeting AL mutations such as D842V in PDGFR α (IC_{50} = 0.24 nmol/L) and D816V in C-KIT (IC_{50} = 0.27 nmol/L). For patients with GISTs harboring D842V in PDGFR α , the objective response rate following avapritinib therapy was 84% (complete response rate of 7%), and 61% of patients experienced remission for ≥ 6 months. In the dose expansion segment, 56 patients with AL mutations in PDGFR α were included, and 49 of these patients had a favorable overall efficacy evaluation, including complete responses in 5 patients (9%) and partial responses in 44 patients (79%) without dose-limiting toxicity. Based on these promising clinical results, avapritinib was approved by the FDA in January 2020 for the treatment of unresectable or metastatic

GISTs in adults with PDGFR α exon 18 mutations, including D842V.

Although avapritinib is effective against GISTs carrying AL mutations in PDGFR α , recent clinical research has demonstrated that patients acquire resistance after treatment. Among them, the solvent front (SF) mutation G680R and the GK residue mutation T674I are the main causes of avapritinib resistance, accounting for more than 40% of cases. In particular, the D842V/G680R dual mutation in PDGFR α accounted for 30% of cases of drug resistance, including a high degree of acquired resistance. Avapritinib has strong activity against D842V-mutated PDGFR α with an IC_{50} of 0.24 nmol/L, whereas the D842V and G680R mutations are associated with IC_{50} values exceeding 1 μ mol/L. Similarly, avapritinib had an IC_{50} of 40 nmol/L for D842V-mutated PDGFR α in a GIST cell model (GIST-T1), whereas its IC_{50} for G680R-mutated PDGFR α exceeded 10 μ mol/L. In addition, the D842V/T674I dual mutation in PDGFR α has been linked to resistance in GISTs-T1 cells with an IC_{50} of 750 nmol/L, and median OS in patients with avapritinib-resistant GISTs is only 5.2 months. The X-ray crystal structure of avapritinib complexed with wild-type PDGFR α (**Fig. 6A**) illustrates that the pyrrolotriazine scaffold N2 nitrogen of avapritinib interacts with C677 in the hinge region via a hydrogen bond. In addition, there is a water-mediated interaction between N4 of the pyrrolotriazine scaffold of avapritinib and T674. Although there is no direct interaction between avapritinib and G680, the structures are separated by approximately 4 Å, suggesting the mutation to arginine introduces a steric clash with the more sterically demanding guanidinium group. Conversely, the GK mutation T674I breaks the water-mediated interaction between avapritinib and T674, resulting in reduced binding affinity and ultimately resistance (**Fig. 6B**).^{29,30}

Similarly, avapritinib effectively inhibits C-KIT carrying the D816V mutation (IC_{50} = 3.8 nmol/L), but it has little activity against C-KIT carrying the GK mutation T670I (IC_{50} = 270 nmol/L).³¹ The X-ray crystal structure of avapritinib complexed with wild-type C-KIT (**Fig. 7A**) and T670I-mutated C-KIT (**Fig. 7B**) revealed a comparable binding mode and resistance mechanism as observed for PDGFR α .³⁰

In general, avapritinib can effectively overcome several forms of clinically acquired resistance to first- to third-line type II kinase drugs, especially resistance associated with AL mutations. However, secondary mutations that confer avapritinib resistance are found in the SF and GK regions. There is an urgent need for next-generation C-KIT/PDGFR α inhibitors to overcome avapritinib-resistant mutations.

Small-Molecule Kinase Inhibitors in Clinical Development

Although the approved C-KIT/PDGFR α inhibitors have provided therapeutic benefits in patients with GISTs, secondary mutations conferring drug resistance remain a challenge. In this section, we briefly summarize the progress and optimization strategies of C-KIT/PDGFR α small-molecule inhibitors that are in clinical development (**Table 3**).




Fig. 6 The co-crystal structures of avapritinib bound to (A) wild-type PDGFR α (PDB ID: 8PQJ) and (B) PDGFR α T674I (PDB ID: 8PQH). Solvent front residue G680 is mutated to R680, which is displayed simply as G680R.

Crenolanib (CP-868596)

Crenolanib is a selective type I PDGFR α inhibitor with highly potent activity against the D842V mutation (IC_{50} = 10 nmol/L). Moreover, crenolanib has better inhibitory activity against the avapritinib resistance mutation D842V/T674I in PDGFR α with an IC_{50} of approximately 20 nmol/L in CHO cells.³² However, crenolanib is relatively ineffective against the PDGFR α V561D and D842V/G680R mutants, with IC_{50} values of approximately 400 nmol/L in CHO cells and 10 μ mol/L in GIST-T1 cells. The X-ray crystal structure of crenolanib complexed with PDGFR α T674I demonstrated that the imidazole nitrogen and amine of crenolanib form hydrogen bonds with C677 and R822, respectively, of the kinase.

Moreover, crenolanib does not collide with the mutated GK residue T674I, which explains its ideal inhibitory activity against the GK mutants T674I and D842V/T674I (**Fig. 8**). Crenolanib is currently being evaluated in a phase III clinical trial for the treatment of GISTs in patients carrying the D842V mutation (NCT02847429).

Bezuclastinib (CGT9486)

Bezuclastinib is a type I C-KIT inhibitor developed by Cogent Biosciences. The X-ray crystal structure of bezuclastinib complexed with C-KIT illustrated that the 1*H*-pyrrolo[2,3-*b*] pyridine scaffold forms two hydrogen bonds with C673 in the hinge region, and the NH of the amide forms a hydrogen




Fig. 7 The co-crystal structures of avapritinib bound to (A) wild-type C-KIT (PDB ID: 8PQ9) and (B) C-KIT T670I (PDB ID: 8PQG).

Table 3 Small-molecule C-KIT/PDGFRα inhibitors in clinical research for the treatment of GISTs

Name	Structure	Organization	Type	Target	Efficacy	Status (clinical trial number)
Crenolanib		Arog Pharmaceuticals	I	PDGFRα, FLT3	PDGFRα D842V	III (NCT02847429)
Bezuclastinib		Cogent Biosciences	I	C-KIT	C-KIT D816V, V560G/D816V	III (NCT05208047)
NB003		AstraZeneca	II	C-KIT, PDGFRα	pan C-KIT mutants	I (NCT04936178)
THE-630	/	Theseus Pharmaceuticals	/	C-KIT	pan C-KIT mutants	Discontinued
IDRX-42		IDRX	II	C-KIT	pan C-KIT mutants	I (NCT05489237)

Note: Data are updated up to February 24, 2024.

bond with the GK residue T670. In addition, the dimethylpyrazole forms hydrogen bonds with E640 and D810 (►Fig. 9). Bezuclastinib is effective against C-KIT carrying primary mutations (exons 9 and 11) and AL mutations (exons 17 and 18).³³ In imatinib-resistant BaF3 cells, bezuclastinib potentially inhibited C-KIT carrying the D816V and V560-G/D816V mutations with IC₅₀ values of 6.6 and 7.1 nmol/L, respectively, representing approximately 300- to 600-fold greater potency than achieved by imatinib.³⁴ Because of its complementary C-KIT mutant inhibition profiles, bezuclastinib is a potent combination partner for sunitinib, which has activities against ATP-binding pocket mutations (exons 13 and 14). Preliminary data indicate that bezuclastinib and sunitinib can be safely combined to achieve improved clinical outcomes in patients with heavily pretreated GISTs, with median PFS reaching 12.1 months.³⁵ Currently, a phase III randomized trial of bezuclastinib plus sunitinib in subjects with GISTs (NCT05208047) is ongoing.

NB003 (AZD3229)

NB003, a selective type II C-KIT/PDGFRα inhibitor, displays potent inhibitory activity against multiple primary and imatinib-resistant secondary mutations in GISTs.³⁶ Kettle et al reported a detailed optimization process for NB003. Inspired by the potent C-KIT inhibitory activity of compound 1³⁷ (AZD2932) and the high C-KIT/kinase insert domain receptor (KDR) selectivity of compound 2,³⁸ compound 3 was designed by incorporating two potent fragments from both compounds (►Fig. 10). Indeed, compound 3 exhibited improved activity against three C-KIT cell lines, but its selectivity against vascular endothelial growth factor receptor 2 (VEGFR2; also known as KDR) was lost. Next, reversing the acetamide linker and removing the methoxy on the phenyl ring generated compound 4, which displayed enhanced selectivity. Furthermore, replacement of the isopropyl imidazole of 4 with isopropyl triazole gave the more potent compound 5, which had improved selectivity over




Fig. 8 The binding mode of crenolanib complexed with PDGFR α T674I (PDB ID: 6JOI).




Fig. 9 The crystal structure of bezuclastinib complexed with C-KIT (PDB ID: 7KHK).

VEGFR2. Optimization of the two methoxyl groups in quinazoline with fluoro and methoxyethyl moieties led to NB003 (**6**), which exhibited at least 400-fold higher selectivity against KDR at least 400-fold. NB003 displayed excellent potency for C-KIT

(GI_{50} = 1 nmol/L) and PDGFR α (GI_{50} = 3 nmol/L) with almost 1,000-fold selectivity over VEGFR2 (GI_{50} = 1,378 nmol/L) in Ba/F3 cells. *In vivo* studies also found that NB003 exerted durable inhibition in patient-derived xenograft models of




Fig. 10 Optimization process of NB003 based on compounds 1 and 2.




Fig. 11 The binding mode of NB003 complexed with C-KIT (PDB ID: 6GQM).

GISTs.³⁹ A co-crystal structure was solved between NB003 and C-KIT, illustrating that NB003 is a type II inhibitor that binds to the DFG-out inactive conformation of C-KIT. The quinazoline moiety interacts with C673 in the hinge region and forms a water-mediated interaction with the GK residue T670. The acetamide forms a water-mediated interaction with the conserved residues K623 and E640. The triazole fragment inserts into the DFG-out pocket and stabilizes the bound waters in C-KIT (►Fig. 11). Ultimately, NB003 has progressed to phase I clinical development based on its optimal C-KIT activity, selectivity over VEGFR2, and pharmacokinetic properties (NCT04936178).

THE-630

THE-630 has displayed extensive inhibition of primary and secondary C-KIT mutants in early clinical development.

THE-630 exhibits high potency ($IC_{50} \leq 3$ nmol/L) in GIST-T1 and BaF3 cells featuring exon 11 deletion and an activating insertion in exon 9, respectively.⁴⁰ In addition, THE-630 has excellent inhibitory activities against ATP-binding pocket and secondary AL mutants (e.g., V654A, T670I, D816G/H) with $IC_{50} \leq 25$ nmol/L. THE-630 exhibited antitumor activity and tolerable safety in patients with advanced GISTs (NCT05160168) in a phase I/II study. However, the phase I/II clinical study of THE630 in patients with GISTs was terminated in 2023.

IDRX-42 (M-4205)

IDRX-42 is a selective type II C-KIT inhibitor with extensive activity against clinically relevant C-KIT mutants and outstanding biochemical and cellular properties. Blum et al reported the optimization process of IDRX-42 in detail.⁴¹ Optimization of the hit compound **7** focused on improving its metabolic stability and cellular potency by incorporating pyrimidine and hydrophilic groups such as methylimidazole and ethoxymethoxy to obtain compound **8**, which featured improved cellular potency and metabolic stability. To explore its druggability, further optimization of **8** using various hydrophilic groups instead of ethoxymethoxy led to IDRX-42 (**9**), which displayed therapeutic efficacy and high metabolic stability (►Fig. 12). IDRX-42 exhibited an IC_{50} of 59 nmol/L in the imatinib-resistant cell line GIST430/654 (exon 11 and 13 mutations), but it was relatively ineffective in cells carrying the GK mutation T670I and AL mutation D816V in C-KIT ($IC_{50} = 367$ and 522 nmol/L, respectively). The co-crystal structure of IDRX-42 complexed with C-KIT illustrated that the imidazo [1,2-*a*] pyridine nitrogen forms a hydrogen bond with C673, and the NH moiety interacts with the GK residue T670, which explains the decreased activity of the drug against GK mutations. In addition, the terminal benzylic substituent forms a π -interaction with W557, and the pyrimidine nitrogen has water-mediated interactions with D810 and K623 (►Fig. 13). Currently, IDRX-42 is in phase I development for the treatment of metastatic and/or




Fig. 12 Optimization process of IDRX-42 based on the hit compound **7**.




Fig. 13 The binding mode of IDRX-42 complexed with C-KIT (PDB ID: 7ZW8).

unresectable GISTs (NCT05489237), and it has received orphan drug designation from the FDA for the treatment of GISTs.

Conclusion and Perspectives

The approved first- to fourth-line drugs and avapritinib, as effective targeted therapies for GISTs, exert excellent inhibitory activity against the vast majority of C-KIT/PDGFR α mutations. Despite the significant clinical benefits of these treatments, their clinical application is limited by SF and GK mutation-mediated clinical resistance. The development of next-generation C-KIT/PDGFR α inhibitors that can overcome acquired resistance to avapritinib is a research hotspot and unmet clinical need. Currently, there are multiple TKIs in clinical development for GIST treatment, such as crenolanib, bezuclastinib, NB003, and IDRX-42. These drugs could represent additional treatment options for GISTs, especially for patients who harbor secondary drug resistance mutations.

The SF mutation G680R in PDGFR α causes steric hindrance with the methylpyrazole of avapritinib, leading to poor inhibitory potency. Similarly, an SF mutation also arises in RTK after treatment with the first-generation TKI larotrectinib. The second-generation macrocycle-based TKIs selitrectinib⁴² and repotrectinib⁴³ can effectively inhibit SF mutations by avoiding clashes with the mutant residues. Therefore, reasonable macrocyclization could represent an effective strategy to overcome SF mutations in PDGFR α . In addition, GK mutations are the most common mutations in acquired drug resistance, and they inevitably emerge in C-KIT (T670I) and PDGFR α (T674I) with similar resistance mech-

anisms. GK mutations, namely T670I in C-KIT and T674I in PDGFR α , disrupt the water-mediated interaction of avapritinib with T670 in KIT and T674 in PDGFR α , resulting in reduced binding affinity. A GK mutation from lysine to leucine (T315I) also occurs in ABL kinase. Ponatinib avoids a steric clash with I315 via an alkyne linker and additionally forms favorable van der Waals interactions with I315, resulting in favorable inhibitory activity.⁴⁴ Thus, avoiding steric hindrance or increasing additional interactions, e.g., hydrogen bonds or hydrophobic interactions, to compensate for lost interactions attributable to GK mutations could represent a strategy to increase the binding affinity of compounds with GK mutant kinases.⁴⁵ In addition to on-target resistance, overactivation of bypass signaling or downstream pathways is also an important factor leading to resistance in GISTs. Nevertheless, the review provides a solid foundation for the discovery of next-generation C-KIT/PDGFR α inhibitors for overcoming clinical resistance in GIST treatment.

Funding

This work was financially supported by the National Natural Science Foundation of China (Grant Nos. 82273763 and 82103968), the International Cooperation Project of Guangdong Science and Technology Program (Grant No. 2022A0505050045), Guangdong Basic and Applied Basic Research Foundation (Grant No. 2022B515130008), the Open Project of State Key Laboratory of Respiratory Disease (Grant No. SKLRD-OP-202313), and Wang Kuancheng Young Scholar of Jinan University and the High-Performance Public Computing Service Platform of Jinan University.

Conflict of Interest

None declared.

References

- Duensing A, Heinrich MC, Fletcher CD, Fletcher JA. Biology of gastrointestinal stromal tumors: KIT mutations and beyond. *Cancer Invest* 2004;22(01):106–116
- Vincenzi B, Nannini M, Fumagalli E, et al. Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis. *Oncotarget* 2016;7(43):69412–69419
- Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of C-KIT in human gastrointestinal stromal tumors. *Science* 1998; 279(5350):577–580
- Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. *Science* 2003;299 (5607):708–710
- Zheng Y, Zheng X, Li S, et al. Identification of key genes and pathways in regulating immune-induced diseases of dendritic cells by bioinformatic analysis. *Mol Med Rep* 2018;17(06): 7585–7594
- Gajiwala KS, Wu JC, Christensen J, et al. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. *Proc Natl Acad Sci U S A* 2009;106(05):1542–1547

- 7 Heldin CH, Lennartsson J, Westermark B. Involvement of platelet-derived growth factor ligands and receptors in tumorigenesis. *J Intern Med* 2018;283(01):16–44
- 8 Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. *Science* 2002;298(5600):1912–1934
- 9 Nocka K, Buck J, Levi E, Besmer P. Candidate ligand for the C-KIT transmembrane kinase receptor: KL, a fibroblast derived growth factor stimulates mast cells and erythroid progenitors. *EMBO J* 1990;9(10):3287–3294
- 10 Mol CD, Lim KB, Sridhar V, et al. Structure of a C-KIT product complex reveals the basis for kinase transactivation. *J Biol Chem* 2003;278(34):31461–31464
- 11 Klug LR, Kent JD, Heinrich MC. Structural and clinical consequences of activation loop mutations in class III receptor tyrosine kinases. *Pharmacol Ther* 2018;191:123–134
- 12 von Mehren M, Joensuu H. Gastrointestinal stromal tumors. *J Clin Oncol* 2018;36(02):136–143
- 13 Dibb NJ, Dilworth SM, Mol CD. Switching on kinases: oncogenic activation of BRAF and the PDGFR family. *Nat Rev Cancer* 2004;4(09):718–727
- 14 Duensing A, Medeiros F, McConarty B, et al. Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). *Oncogene* 2004;23(22):3999–4006
- 15 Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. *J Clin Oncol* 2008;26(04):626–632
- 16 Antonescu CR, Besmer P, Guo T, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. *Clin Cancer Res* 2005;11(11):4182–4190
- 17 Chen LL, Trent JC, Wu EF, et al. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. *Cancer Res* 2004;64(17):5913–5919
- 18 Tamborini E, Priol S, Negri T, et al. Functional analyses and molecular modeling of two C-KIT mutations responsible for imatinib secondary resistance in GIST patients. *Oncogene* 2006;25(45):6140–6146
- 19 Wardelmann E, Thomas N, Merkelbach-Bruse S, et al. Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. *Lancet Oncol* 2005;6(04):249–251
- 20 Prenen H, Cools J, Mentens N, et al. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. *Clin Cancer Res* 2006;12(08):2622–2627
- 21 Garner AP, Gozgit JM, Anjum R, et al. Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients. *Clin Cancer Res* 2014;20(22):5745–5755
- 22 Reichardt P, Demetri GD, Gelderblom H, et al. Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial. *BMC Cancer* 2016;16:22
- 23 Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. *Lancet* 2006;368(9544):1329–1338
- 24 Demetri GD, Reichardt P, Kang YK, et al; GRID study investigators. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. *Lancet* 2013;381(9863):295–302
- 25 Grothey A, George S, van Cutsem E, Blay JY, Sobrero A, Demetri GD. Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care. *Oncologist* 2014;19(06):669–680
- 26 Smith BD, Kaufman MD, Lu WP, et al. Ripretinib (DCC-2618) is a switch control kinase inhibitor of a broad spectrum of oncogenic and drug-resistant KIT and PDGFRA variants. *Cancer Cell* 2019;35(05):738–751.e9
- 27 Blay JY, Serrano C, Heinrich MC, et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. *Lancet Oncol* 2020;21(07):923–934
- 28 Mühlenberg T, Ketzner J, Heinrich MC, et al. KIT-dependent and KIT-independent genomic heterogeneity of resistance in gastrointestinal stromal tumors - TORC1/2 inhibition as salvage strategy. *Mol Cancer Ther* 2019;18(11):1985–1996
- 29 Grunewald S, Klug LR, Mühlenberg T, et al. Resistance to avapritinib in PDGFRA-driven GIST is caused by secondary mutations in the PDGFRA kinase domain. *Cancer Discov* 2021;11(01):108–125
- 30 Teuber A, Schulz T, Fletcher BS, et al. Avapritinib-based SAR studies unveil a binding pocket in KIT and PDGFRA. *Nat Commun* 2024;15(01):63
- 31 Apse Winger B, Cortopassi WA, Garrido Ruiz D, et al. ATP-competitive inhibitors midostaurin and avapritinib have distinct resistance profiles in exon 17-mutant KIT. *Cancer Res* 2019;79(16):4283–4292
- 32 Heinrich MC, Griffith D, McKinley A, et al. Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors. *Clin Cancer Res* 2012;18(16):4375–4384
- 33 Bollag G. Abstract IA32: Optimizing kinase inhibitors to treat cancer. *Cancer Res* 2016;76(3, supplement):IA32
- 34 Gebreyohannes YK, Burton EA, Wozniak A, et al. PLX9486 shows anti-tumor efficacy in patient-derived, tyrosine kinase inhibitor-resistant KIT-mutant xenograft models of gastrointestinal stromal tumors. *Clin Exp Med* 2019;19(02):201–210
- 35 Wagner AJ, Severson PL, Shields AF, et al. Association of combination of conformation-specific KIT inhibitors with clinical benefit in patients with refractory gastrointestinal stromal tumors: a phase 1b/2a nonrandomized clinical trial. *JAMA Oncol* 2021;7(09):1343–1350
- 36 Kettle JG, Anjum R, Barry E, et al. Discovery of *N*-(4-[5-fluoro-7-(2-methoxyethoxy)quinazolin-4-yl]aminophenyl)-2-[4-(propan-2-yl)-1*H*-1,2,3-triazol-1-yl]acetamide (AZD3229), a potent Pan-KIT mutant inhibitor for the treatment of gastrointestinal stromal tumors. *J Med Chem* 2018;61(19):8797–8810
- 37 Plé PA, Jung F, Ashton S, et al. Discovery of AZD2932, a new quinazoline ether inhibitor with high affinity for VEGFR-2 and PDGFR tyrosine kinases. *Bioorg Med Chem Lett* 2012;22(01):262–266
- 38 Plé PA, Jung F, Ashton S, et al. Discovery of new quinoline ether inhibitors with high affinity and selectivity for PDGFR tyrosine kinases. *Bioorg Med Chem Lett* 2012;22(09):3050–3055
- 39 Banks E, Grondine M, Bhavsar D, et al. Discovery and pharmacological characterization of AZD3229, a potent KIT/PDGFR α inhibitor for treatment of gastrointestinal stromal tumors. *Sci Transl Med* 2020;12(541):eaaz2481
- 40 Rivera VM, Huang WS, Lu MR, Pritchard JR, Dalgarno D, Shakespeare WC. Abstract 1292: Preclinical characterization of THE-630, a next-generation inhibitor for KIT-mutant gastrointestinal stromal tumors (GIST). *Cancer Res* 2021;81(13, supplement):1292
- 41 Blum A, Dorsch D, Linde N, et al. Identification of M4205—a highly selective inhibitor of KIT mutations for treatment of unresectable metastatic or recurrent gastrointestinal stromal tumors. *J Med Chem* 2023;66(04):2386–2395
- 42 Drilon A, Nagasubramanian R, Blake JF, et al. A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK

- kinase inhibition in patients with TRK fusion-positive solid tumors. *Cancer Discov* 2017;7(09):963–972
- 43 Drilon A, Ou SI, Cho BC, et al. Repotrectinib (TPX-0005) is a next-generation ROS1/TRK/ALK inhibitor that potently inhibits ROS1/TRK/ALK solvent-front mutations. *Cancer Discov* 2018;8(10):1227–1236
- 44 Huang WS, Metcalf CA, Sundaramoorthi R, et al. Discovery of 3-[2-(imidazo[1,2-*b*]pyridazin-3-yl)ethynyl]-4-methyl-*N*-4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenylbenzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant. *J Med Chem* 2010;53(12):4701–4719
- 45 Zhou Y, Xiang S, Yang F, Lu X. Targeting gatekeeper mutations for kinase drug discovery. *J Med Chem* 2022;65(23):15540–15558